Letter to the editor
Management of β-agonist overuse: Why and how?

https://doi.org/10.1016/j.jaci.2008.07.025Get rights and content

References (11)

There are more references available in the full text version of this article.

Cited by (0)

Disclosure of potential conflict of interest: D. R. Taylor has received speaker's fees from AstraZeneca New Zealand and Aerocrine AB, Sweden. D. Hannah has declared that she has no conflict of interest.

View full text